Finally, dual mTORC1/C2 inhibitors such as Torin1 and Torin2 were shown to suppress hypertrophy, senescent morphology and extend CLS of human fibroblasts even better compared to rapamycin, suggesting that at doses lower than anti-cancer concentrations, pan-mTOR inhibitors could be developed as anti-ageing interventions [192]. The gene discussed is MTOR; the disease is cancer.